0
Multiple Sclerosis Collection
The most recent journal, In the Clinic, and Summaries for Patients articles
Therapeutics |  May/Jun 2002
Review: In relapsing-remitting multiple sclerosis, recombinant interferon reduces exacerbations in the first 2 treatment years
Jock Murray, MD
Ann Intern Med. 2002;136(3):104. doi:10.7326/ACPJC-2002-136-3-104
Book Notes |  1 October 1991
Handbook of Multiple Sclerosis
Ann Intern Med. 1991;115(7):583. doi:10.7326/0003-4819-115-7-583_3
Diagnosis and Treatment |  1 July 1986
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
TODD D. SHENKENBERG, M.D.; DANIEL D. VON HOFF, M.D.
Ann Intern Med. 1986;105(1):67-81. doi:10.7326/0003-4819-105-1-67
In the Clinic |  1 April 2014
Multiple Sclerosis
Daniel M. Harrison, MD
Ann Intern Med. 2014;160(7):ITC4-1. doi:10.7326/0003-4819-160-7-201404010-01004
ACP Journal Club |  18 March 2014
Review: In relapsing–remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates
Brian G. Weinshenker, MD, FRCP(C)
Ann Intern Med. 2014;160(6):JC5. doi:10.7326/0003-4819-160-6-201403180-02005
ACP Journal Club |  18 May 2010
Oral fingolimod was more effective than intramuscular interferon for relapsing–remitting multiple sclerosis
James Hughes, MD
Ann Intern Med. 2010;152(10):JC5-6. doi:10.7326/0003-4819-152-10-201005180-02006
ACP Journal Club |  18 May 2010
Oral fingolimod was more effective than placebo for relapsing–remitting multiple sclerosis
James Hughes, MD
Ann Intern Med. 2010;152(10):JC5-7. doi:10.7326/0003-4819-152-10-201005180-02007
Advertisement
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)